2024
Tumor expressed BCAM impedes anti-tumor T cell immunity and can be targeted therapeutically
Flies D, Tian L, O'Neill R, Fitzgerald D, Sharee S, Shaik J, Bosiacki J, Paucarmayta A, Prajapati K, Langermann S, Mrass P. Tumor expressed BCAM impedes anti-tumor T cell immunity and can be targeted therapeutically. The Journal Of Immunology 2024, 212: 0517_5466-0517_5466. DOI: 10.4049/jimmunol.212.supp.0517.5466.Peer-Reviewed Original ResearchAnti-tumor immunityT cell immunityCytotoxic T cellsTumor microenvironmentT cellsTumor growthAnti-tumor T cell immunityT cell anti-tumor immunityExclusion of T cellsIncreased T-cell infiltrationRegulating T cell immunityHuman T cell functionT cell infiltrationInhibitor of T cell proliferationT cell suppressionHuman tumors in vitroT cell functionReduced tumor growthT cell proliferationDecreased tumor growthTumors in vitroTumor growth in vivoCancer escapeCheckpoint inhibitorsGrowth in vivo
2019
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells.
Ventura A, Vassall A, Yurter A, Robinson E, Filler R, Hanlon D, Meeth K, Ezaldein H, Girardi M, Sobolev O, Bosenberg MW, Edelson RL. Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells. Journal Of Visualized Experiments 2019 PMID: 31157760, DOI: 10.3791/59370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaDendritic cellsCellular vaccinesClinical efficacyAnti-tumor T cell immunityVivo anti-tumor responsesMonocyte-derived dendritic cellsTumor cellsSyngeneic mouse tumor modelsImmunogenic dendritic cellsAnti-cancer immunityT cell immunityAnti-tumor responseHuman dendritic cellsT-cell lymphomaAnti-tumor effectsKey mechanistic driversApoptotic tumor cellsMouse tumor modelsCell immunitySafety profileCancer immunotherapyCell lymphomaMouse modelBlood samples
2017
Single-cell cytokine profiling of tumor-infiltrating T cells to measure patient responses to anti-PD-1 therapy.
Mackay S, Flynn B, Morse K, Paczkowski P, Bacchiocchi A, Fan R, Halaban R, Zhou J. Single-cell cytokine profiling of tumor-infiltrating T cells to measure patient responses to anti-PD-1 therapy. Journal Of Clinical Oncology 2017, 35: 49-49. DOI: 10.1200/jco.2017.35.7_suppl.49.Peer-Reviewed Original ResearchTumor-infiltrating T lymphocytesAnti-PD-1 therapyClinical outcomesCytokine profilingAnti-tumor T cell functionAnti-tumor T cell immunityTumor-infiltrating T cellsMIP-1 αAnti-tumor immunityT cell immunityResponse of patientsT cell functionCell immunityCheckpoint immunotherapyMelanoma patientsIL-8Metastatic melanomaCancer patientsTIL functionTIL analysisPatient responseT cellsT lymphocytesGranzyme BImmune function
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply